Pharmaceutical

Travere signs $120m licensing deal with Renalys for sparsentan in Asia

Renalys plans to start a registrational trial for sparsentan as a treatment for IgA nephropathy in Japan in Q2 2024.

Jan 27, 2024 - 18:00
Travere signs $120m licensing deal with Renalys for sparsentan in Asia
Renalys plans to start a registrational trial for sparsentan as a treatment for IgA nephropathy in Japan in Q2 2024.
Read the original article

Tags:

Previous Article

FDA expands approval of Dupixent for eosinophilic esophagitis in children

Next Article

STAT+: From a small town in Wales, a scientific sleuth has shaken Dana-Farber — ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

SciRhom secures $70m for autoimmune diseases treatments

SciRhom secures $70m for autoimmune diseases treatments

Jul 10, 2024

Sildenafil citrate by XOMA Royalty for Female Hypoactiv...

Sep 10, 2024

Marker to offload cell manufacturing assets to CellReady

Marker to offload cell manufacturing assets to CellReady

May 2, 2023